NU-VERAP SR TABLET (EXTENDED-RELEASE)

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

VERAPAMIL HYDROCHLORIDE

Saadav alates:

NU-PHARM INC

ATC kood:

C08DA01

INN (Rahvusvaheline Nimetus):

VERAPAMIL

Annus:

240MG

Ravimvorm:

TABLET (EXTENDED-RELEASE)

Koostis:

VERAPAMIL HYDROCHLORIDE 240MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0113846003; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2012-09-04

Toote omadused

PRODUCT MONOGRAPH
NU-VERAP SR
VERAMAPIL HYDROCHLORIDE SUSTAINED RELEASE TABLETS
NU-PHARM STANDARD
120 MG, 180 MG AND 240 MG
ANTIHYPERTENSIVE AGENT
NU-PHARM INC.
DATE OF REVISION:
50 MURAL STREET, UNITS 1 & 2
OCTOBER 20, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
_ _
CONTROL#: 133484
1
PRODUCT MONOGRAPH
NU-VERAP
SR
Verapamil Hydrochloride Sustained Release Tablets
Apotex Standard
120 mg, 180 mg and 240 mg
THERAPEUTIC CLASSIFICATION
Antihypertensive Agent
ACTION AND CLINICAL PHARMACOLOGY
Verapamil hydrochloride is a calcium ion influx inhibitor (calcium
entry blocker or calcium ion
antagonist) that exerts its pharmacological effects by modulating the
influx of ionic calcium across
the cell membrane of the arterial smooth muscle as well as in
conducting and contractile
myocardial cells.
Verapamil exerts antihypertensive effects by inducing vasodilation and
reducing peripheral
vascular resistance usually without reflex tachycardia. Verapamil does
not blunt hemodynamic
response to isometric or dynamic exercise.
Verapamil depresses A-V nodal conduction and prolongs functional
refractory periods. Verapamil
does not alter the normal atrial action potential or intraventricular
conduction time, but depresses
amplitude, velocity of depolarization and conduction in depressed
atrial fibres.
Verapamil may shorten the antegrade effective refractory period of the
accessory bypass tract.
Acceleration of ventricular rate and/or ventricular fibrillation has
been reported in patients with
atrial flutter or atrial fibrillation and a coexisting accessory A–V
pathway following administration
2
of verapamil (see WARNINGS - Conduction Disturbance). Verapamil has a
local anaesthetic
action that is 1.6 times that of procaine on an equimolar basis.
Verapamil is a potent smooth muscle relaxant with vasodilatory
properties, as well as a
depressant of myocardial contractility, and these effects are largely
independent of autonomic
influences.
Compared to baseline, verapamil administration did not affect
electrolytes, glucose, and
creatinine. The hy